- Home
- / InCarda Therapeutics
InCarda Therapeutics
Total Funding
$47.6 M
InCarda Therapeutics Summary
Company Summary
- Overview
- InCarda Therapeutics is a biopharmaceutical company that develops cardiovascular treatments. It develops an inhaled therapy to deliver flecainide to the heart via the lungs to treat a common atrial arrhythmia and paroxysmal atrial fibrillation.
- Type
- Private
- Status
- Active
- Founded
- 2009
- HQ
- Newark, CA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Carlos Schuler, Chief Executive Officer & Co-Founder
Luiz Belardinelli, Chief Medical Officer
Meisa Propst, Vice President, Clinical Operations
LocationsView all
2 locations detected
Newark, CA HQ
United States
39899 Balentine Dr Suite 185
Melbourne, VIC
Australia
level 13/41 Exhibition St